Dan Ruan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan Ruan has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Haojun Chen
Department of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
13 shared publications - Hua Wu
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
13 shared publications - Liang Zhao
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
13 shared publications - Long Sun
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
13 shared publications - Hao Fu
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
12 shared publications - Hui Zhou
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
12 shared publications
Latest Publications
- 1 August 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (2)
68 Ga-NK224 PET/CT Reveals Intra- and Intertumoral Heterogeneity of PD-L1 in Non–Small Cell Lung Cancer
68 Ga-NK224 PET/CT enabled whole-body assessment of programmed death ligand 1 heterogeneity in participants with non–small cell lung cancer and revealed lesion-level heterogeneity not captured through biopsies; 68 Ga-NK224 uptake was associated with immunotherapy response.
- 1 August 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (2)
68 Ga-NK224 PET/CT Reveals Intra- and Intertumoral Heterogeneity of PD-L1 in Non–Small Cell Lung Cancer
68 Ga-NK224 PET/CT enabled whole-body assessment of programmed death ligand 1 heterogeneity in participants with non–small cell lung cancer and revealed lesion-level heterogeneity not captured through biopsies; 68 Ga-NK224 uptake was associated with immunotherapy response.
- 20 August 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 106, 103771
Paired phase and magnitude reconstruction neural network for multi-shot diffusion magnetic resonance imaging
- 20 August 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 106, 103771
Paired phase and magnitude reconstruction neural network for multi-shot diffusion magnetic resonance imaging
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S6. Representative 18F-FDG and 68Ga-NK224 PET/CT maximum intensity projection images of patients with varying PD-L1 expression levels: Patient A: 18F-FDG SUVmax 15.3, 68Ga-NK224 SUVmax 8.2, PD-L1 TPS 80%; Patient B: 18F-FDG SUVmax 10.1, 68Ga-NK224 SUVmax 4.8, PD-L1 TPS 2; Patient C: 18F-FDG SUVmax 10.4, 68Ga-NK224 SUVmax 2.2, PD-L1 TPS <1%.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S6. Representative 18F-FDG and 68Ga-NK224 PET/CT maximum intensity projection images of patients with varying PD-L1 expression levels: Patient A: 18F-FDG SUVmax 15.3, 68Ga-NK224 SUVmax 8.2, PD-L1 TPS 80%; Patient B: 18F-FDG SUVmax 10.1, 68Ga-NK224 SUVmax 4.8, PD-L1 TPS 2; Patient C: 18F-FDG SUVmax 10.4, 68Ga-NK224 SUVmax 2.2, PD-L1 TPS <1%.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Table S2. Representativeness of Study Participants.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Table S2. Representativeness of Study Participants.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S4. (A-B) PD-L1 expression in A549 and A549-hPD-L1 cells assessed by flow cytometry. (C) Cell uptake assay of 68Ga-NK224 in A549 and A549-hPD-L1cells, including blocking studies with an unlabeled precursor to confirm specificity (n=3/group).
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S4. (A-B) PD-L1 expression in A549 and A549-hPD-L1 cells assessed by flow cytometry. (C) Cell uptake assay of 68Ga-NK224 in A549 and A549-hPD-L1cells, including blocking studies with an unlabeled precursor to confirm specificity (n=3/group).
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S3. The liquid chromatography–mass spectrometry of NK224.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S3. The liquid chromatography–mass spectrometry of NK224.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Table S1. Participant characteristics.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Table S1. Participant characteristics.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Table S3. Detailed data of 68Ga-NK224 uptake in tumors at baseline and on days 1, 3, 5, and 7 following hPD-L1 antibody administration.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Table S3. Detailed data of 68Ga-NK224 uptake in tumors at baseline and on days 1, 3, 5, and 7 following hPD-L1 antibody administration.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S1. Synthesis flow diagram of NK224.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S1. Synthesis flow diagram of NK224.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S5. Quantification of PET image results showing U87-MG tumor uptake for different radiotracers, with or without a competitor, at 1 hour post-injection.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from 68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
Supplementary Figure S5. Quantification of PET image results showing U87-MG tumor uptake for different radiotracers, with or without a competitor, at 1 hour post-injection.